Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Completes Acquisition of Icoria in $11M All-Stock Deal

NEW YORK, Dec. 21 (GenomeWeb News) - Clinical Data said yesterday that it has closed its acquisition of Icoria.


Under the terms of the agreement, Clinical Data will issue 0.01552 of its own shares for each outstanding share of Icoria common stock, representing a price of $.28 per Icoria share based on Clinical Data's share price in mid-afternoon trading. The total value of the transaction is approximately $11 million.


Clinical Data initially announced its intention to acquire Icoria in September, and pegged the value of the deal at around $12.5 million. At the time, it said it would issue 0.0139 of its own shares for each share of Icoria common stock, which represented $.32 per Icoria share.


Icoria will cease trading on the OTC Bulletin Board under the ticker symbol ICOR.OB "immediately," Clinical Data said.


In conjunction with the acquisition, Steven Burrill, formerly chairman of Icoria's board of directors, will join Clinical Data's board, bringing the total number of directors to eight.


Israel Stein, president and CEO of Clinical Data, said in a statement that Icoria's metabolomics and gene expression capabilities "will significantly enhance the pharmacogenomics technologies we acquired through our merger with Genaissance Pharmaceuticals."


The company purchsed Genaissance in a $56 million all-stock transaction that closed in October.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.